| Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, ... autophagy 17 (1), 1-382, 2021 | 13752* | 2021 |
| KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene GS Wu, TF Burns, ER McDonald 3rd, W Jiang, R Meng, ID Krantz, G Kao, ... Nature genetics 17 (2), 141-143, 1997 | 1425 | 1997 |
| Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiPl K Somasundaram, H Zhang, YX Zeng, Y Houvras, Y Peng, H Zhang, ... Nature 389 (6647), 187-190, 1997 | 713 | 1997 |
| p53-dependent and -independent Regulation of the Death Receptor KILLER/DR5 Gene Expression in Response to Genotoxic Stress and Tumor Necrosis Factor α MS Sheikh, TF Burns, Y Huang, GS Wu, S Amundson, KS Brooks, ... Cancer research 58 (8), 1593-1598, 1998 | 524 | 1998 |
| Notch signaling: an emerging therapeutic target for cancer treatment X Yuan, H Wu, H Xu, H Xiong, Q Chu, S Yu, GS Wu, K Wu Cancer letters 369 (1), 20-27, 2015 | 464 | 2015 |
| The functional interactions between the MAPK and p53 signaling pathways GS Wu Cancer biology & therapy 3 (2), 156-161, 2004 | 420 | 2004 |
| Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects JE Allen, G Krigsfeld, PA Mayes, L Patel, DT Dicker, AS Patel, NG Dolloff, ... Science translational medicine 5 (171), 171ra17-171ra17, 2013 | 349 | 2013 |
| Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor GS Wu, TF Burns, Y Zhan, ES Alnemri, WS El-Deiry Cancer research 59 (12), 2770-2775, 1999 | 315 | 1999 |
| Role of autophagy in cisplatin resistance in ovarian cancer cells J Wang, GS Wu Journal of Biological chemistry 289 (24), 17163-17173, 2014 | 313 | 2014 |
| Potential role for cathepsin D in p53-dependent tumor suppression and chemosensitivity GS Wu, P Saftig, C Peters, WS El-Deiry Oncogene 16 (17), 2177-2183, 1998 | 297 | 1998 |
| Proteasome-dependent regulation of p21WAF1/CIP1Expression MV Blagosklonny, GS Wu, S Omura, WS El-Deiry Biochemical and biophysical research communications 227 (2), 564-569, 1996 | 297 | 1996 |
| Developing TRAIL/TRAIL death receptor-based cancer therapies X Yuan, A Gajan, Q Chu, H Xiong, K Wu, GS Wu Cancer and Metastasis Reviews 37, 733-748, 2018 | 253 | 2018 |
| Repair Defect in p21WAF1/CIP1 -/- Human Cancer Cells ER McDonald III, GS Wu, T Waldman, WS El-Deiry Cancer research 56 (10), 2250-2255, 1996 | 244 | 1996 |
| Rare loss-of-function mutation of a death receptor gene in head and neck cancer SI Pai, GS Wu, N Özören, L Wu, J Jen, D Sidransky, WS El-Deiry Cancer research 58 (16), 3513-3518, 1998 | 214 | 1998 |
| TRAIL as a target in anti-cancer therapy GS Wu Cancer letters 285 (1), 1-5, 2009 | 212 | 2009 |
| Stochastic cancer progression driven by non‐clonal chromosome aberrations HHQ Heng, JB Stevens, G Liu, SW Bremer, KJ Ye, PV Reddy, GS Wu, ... Journal of cellular physiology 208 (2), 461-472, 2006 | 211 | 2006 |
| Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells DJ Peng, J Wang, JY Zhou, GS Wu Biochemical and biophysical research communications 394 (3), 600-605, 2010 | 191 | 2010 |
| Cisplatin resistance associated with PARP hyperactivation J Michels, I Vitale, L Galluzzi, J Adam, KA Olaussen, O Kepp, L Senovilla, ... Cancer research 73 (7), 2271-2280, 2013 | 189 | 2013 |
| Overexpression of BCL2 blocks TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung cancer cells SY Sun, P Yue, JY Zhou, Y Wang, HRC Kim, R Lotan, GS Wu Biochemical and biophysical research communications 280 (3), 788-797, 2001 | 177 | 2001 |
| Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 or bcl-2. GS Wu, WS El-Deiry Clinical cancer research: an official journal of the American Association …, 1996 | 175 | 1996 |
